



# Asymmetric epoxidation catalyzed by esters of $\alpha$ -hydroxy-8-oxabicyclo[3.2.1]octan-3-one

Alan Armstrong,<sup>a,\*</sup> William O. Moss<sup>b</sup> and Jonathan R. Reeves<sup>a</sup>

<sup>a</sup>Department of Chemistry, Imperial College, London SW7 2AY, UK


<sup>b</sup>AstraZeneca R&D Charnwood, Loughborough, Leicestershire, UK

Received 30 October 2001; accepted 5 November 2001


**Abstract**—Several esters of  $\alpha$ -hydroxy-8-oxabicyclo[3.2.1]octan-3-one were prepared and tested as catalysts for alkene epoxidation by Oxone<sup>®</sup>. © 2001 Elsevier Science Ltd. All rights reserved.

## 1. Introduction

Asymmetric alkene epoxidation with Oxone<sup>®</sup> catalyzed by chiral ketones, via dioxirane intermediates, is providing extremely promising results.<sup>1</sup> A major challenge is the development of active catalysts that do not suffer decomposition by Baeyer–Villiger reaction.<sup>2</sup> We have identified bicyclo[3.2.1]octan-3-ones as a class of conformationally well defined catalysts with low intrinsic tendency to undergo decomposition.<sup>3</sup> Our initial study indicated that  $\alpha$ -fluoro-*N*-carboethoxytropinone **1** afforded high activity, allowing use at low loadings at pH 7.5.<sup>3a</sup> Promising enantioselectivities were also recorded.<sup>3a</sup> This work was followed by a study of the corresponding oxabicyclic compound **2** which provided higher enantioselectivity in the epoxidation of (*E*)-stilbene.<sup>3b</sup> Additionally, we found that replacement of the  $\alpha$ -fluoro substituent with an acetoxy group provided further improvement.<sup>3b</sup> Herein, we report further studies on asymmetric epoxidation promoted by these promising oxabicyclic ketones, focusing on the effect of modifying the  $\alpha$ -ester substituent.



- 1** X=NCO<sub>2</sub>Et, Y=F  
**2** X=O, Y=F  
**3** X=O, Y=OH



- a** R=CH<sub>3</sub>  
**b** R=CF<sub>3</sub>  
**c** R=Ph  
**d** R=*p*-NO<sub>2</sub>Ph  
**e** R=*m*-NO<sub>2</sub>Ph  
**f** R=*p*-MeOPh  
**g** R=*m*-MeOPh

## 2. Results and discussion

Since  $\alpha$ -acetoxyketone **4a** gave promising enantioselectivity in the epoxidation of (*E*)-stilbene,<sup>3b</sup> we decided to use the parent alcohol **3<sup>b</sup>** as a starting point for the preparation of several ester derivatives **4**.<sup>5</sup> We were particularly interested in aromatic esters in view of the possibility of  $\pi$ – $\pi$  interactions with aromatic alkene substrates; accordingly, we prepared both electron-rich and electron-poor esters with the substituents at either the *meta*- or *para*-positions in order to probe their effect on epoxidation enantioselectivities. The results for the epoxidation of (*E*)-stilbene using these racemic ketones (20 mol%) under the Yang<sup>4</sup> Oxone<sup>®</sup>/CH<sub>3</sub>CN/H<sub>2</sub>O system (pH ca. 7.5) are shown in Table 1. The trifluoroacetate **4b** showed low conversion (entry 2) due to hydrolysis under the reaction conditions. All of the aromatic esters examined afforded lower conversion than the acetate **4a** (entries 1, 3–7), although they appeared to be stable under the reaction conditions. Perhaps surprisingly, there appeared to be little difference between electron-poor and electron-rich aromatics.

\* Corresponding author. E-mail: a.armstrong@ic.ac.uk

**Table 1.** Epoxidation of (*E*)-stilbene catalyzed by racemic ketones **4a–g**<sup>a</sup>

Entry	Ketone	R	Time (h)	Conversion <sup>b</sup>
1	<b>4a</b>	CH <sub>3</sub>	24	85
2	<b>4b</b>	CF <sub>3</sub>	24	3
3	<b>4c</b>	Ph	24	36
4	<b>4d</b>	<i>p</i> -NO <sub>2</sub> Ph	24	39
5	<b>4e</b>	<i>m</i> -NO <sub>2</sub> Ph	24	46
6	<b>4f</b>	<i>p</i> -MeOPh	24	53
7	<b>4g</b>	<i>m</i> -MeOPh	24	33

<sup>a</sup> Alkene (0.1 mmol), Oxone<sup>®</sup> (1.0 mmol KHSO<sub>5</sub>), ketone (0.02 mmol), NaHCO<sub>3</sub> (1.55 mmol), CH<sub>3</sub>CN (1.5 ml), aq. Na<sub>2</sub>EDTA (1 ml of 0.4 mmol dm<sup>-3</sup> solution), rt.

<sup>b</sup> Estimated by integration of the crude <sup>1</sup>H NMR spectrum.

Starting from alcohol **3** of 72% e.e. obtained by chiral base chemistry as described earlier,<sup>3b,6</sup> the esters were prepared in enantiomerically enriched form and evaluated for asymmetric epoxidation of alkenes with different

substitution patterns: (*E*)-stilbene, styrene and  $\alpha$ -methylstyrene (Table 2). The last two compounds represent terminal alkenes, which are still problematic for asymmetric epoxidation.<sup>7</sup> The esters were assumed to have the same enantiomeric excess as the parent alcohol, and none of the solid esters (**4c**, **4d** and **4f**) were recrystallized. Table 2 includes an 'e.e.<sub>max</sub>' value, the expected product e.e. with enantiomerically pure catalyst based on the assumption that there is a linear relationship between catalyst e.e. and product e.e. We have established that this is indeed the case in the epoxidation of (*E*)-stilbene catalyzed by fluoroketone **2**<sup>8a</sup> and by **4a**.<sup>8b</sup> For the epoxidation of (*E*)-stilbene, all of the aromatic esters **4c–g** afforded lower e.e. than the acetate **4a** (entries 1, 2–6). Amongst the aromatic esters, the nitroaromatics provided higher e.e. than the methoxy analogues (compare entries 3 and 4 to 5 and 6). A similar trend was noted in the epoxidation of styrene. For  $\alpha$ -methylstyrene, selectivities were low in all cases but the methoxyaromatics gave marginally better results than the other catalysts.

**Table 2.** Epoxidation of aromatic alkenes catalyzed by non-racemic ketones **4a–g**<sup>a</sup>

Entry	Ketone	R	<i>(E)</i> -Stilbene <sup>b</sup>		Styrene <sup>c</sup>		$\alpha$ -Methylstyrene <sup>d</sup>	
			Conversion <sup>c</sup>	E.e. <sub>max</sub> <sup>f,g</sup>	Conversion <sup>c</sup>	E.e. <sub>max</sub> <sup>f,h</sup>	Conversion <sup>c</sup>	E.e. <sub>max</sub> <sup>f,i</sup>
1	<b>4a</b>	CH <sub>3</sub>	85	93	100	48	100	10
2	<b>4c</b>	Ph	39	75	100	36	100	11
3	<b>4d</b>	<i>p</i> -NO <sub>2</sub> Ph	41	78	100	35	100	15
4	<b>4e</b>	<i>m</i> -NO <sub>2</sub> Ph	46	81	100	40	100	10
5	<b>4f</b>	<i>p</i> -MeOPh	53	67	100	31	75	19
6	<b>4g</b>	<i>m</i> -MeOPh	24	46	100	25	65	26

<sup>a</sup> Alkene (0.1 mmol), Oxone<sup>®</sup> (1.0 mmol KHSO<sub>5</sub>), ketone (0.02 mmol), NaHCO<sub>3</sub> (1.55 mmol), CH<sub>3</sub>CN (1.5 ml), aq. Na<sub>2</sub>EDTA (1 ml of 0.4 mmol dm<sup>-3</sup> solution), rt, 24 h.

<sup>b</sup> The major isomer had (*R,R*)-configuration in each case.<sup>9</sup>

<sup>c</sup> The major isomer had (*R*)-configuration in each case.<sup>7</sup>

<sup>d</sup> The major isomer had (*S*)-configuration in each case.<sup>7</sup>

<sup>e</sup> Estimated by integration of the crude <sup>1</sup>H NMR spectrum.

<sup>f</sup> E.e.<sub>max</sub> = 100 × product e.e./ketone e.e. All catalysts were derived from alcohol **3** of 72% e.e.

<sup>g</sup> Measured by chiral HPLC (Chiralcel OD column using 10% isopropylalcohol/hexane as eluent).

<sup>h</sup> Measured by chiral GC (Chiraldex GTA column using a thermal ramp 50–180°C).

<sup>i</sup> Measured by chiral HPLC (Chiralcel OD column using 0.8% *iso*-propylalcohol/hexane as eluent).

**Table 3.** Asymmetric epoxidation of alkenes catalyzed by non-racemic ketone **4a**<sup>a</sup>

Entry	Alkene	Conversion <sup>b</sup>	E.e. <sub>max</sub> <sup>c</sup>	Product configuration
1	Styrene	100	48	( <i>R</i> ) <sup>d</sup>
2	$\alpha$ -Methylstyrene	100	10	( <i>S</i> ) <sup>e</sup>
3	( <i>E</i> )-Stilbene	85	93	( <i>R,R</i> ) <sup>c</sup>
4	$\beta$ -Methylstyrene	100	70	( <i>R,R</i> ) <sup>f</sup>
5	Phenylcyclohexene	89	82	( <i>R,R</i> ) <sup>f</sup>
6	Phenylstilbene	71	98	( <i>R,R</i> ) <sup>c</sup>
7	Methyl ( <i>E</i> )-cinnamate	4	84	n.d. <sup>g</sup>
8	2-Cyclohexenone	51	3	( <i>R,R</i> ) <sup>h</sup>

<sup>a</sup> Alkene (0.1 mmol), Oxone<sup>®</sup> (1.0 mmol KHSO<sub>5</sub>), ketone (0.02 mmol), NaHCO<sub>3</sub> (1.55 mmol), CH<sub>3</sub>CN (1.5 mL), aq. Na<sub>2</sub>EDTA (1 ml of 0.4 mmol dm<sup>-3</sup> solution), rt, 24 h.

<sup>b</sup> Estimated by integration of the crude <sup>1</sup>H NMR spectrum.

<sup>c</sup> E.e.<sub>max</sub> = 100 × product e.e./ketone e.e. Catalyst **4a** used was of 82% e.e. in all cases, except for entries 2, 5 and 6 where **4a** was of 72% e.e.

<sup>d</sup> Product e.e. and configuration were determined by chiral GC.<sup>7</sup>

<sup>e</sup> Product e.e. and configuration determined by chiral HPLC analysis.<sup>7</sup>

<sup>f</sup> Product e.e. and configuration determined by chiral shift reagent <sup>1</sup>H NMR analysis.<sup>9</sup>

<sup>g</sup> Configuration not determined.

<sup>h</sup> Product e.e. determined by GC; configuration determined by comparing the measured optical rotation with the reported one.<sup>10</sup>

Since the  $\alpha$ -acetoxyketone **4a** appeared to be the best of the esters examined, we investigated its use in the epoxidation of a wider range of alkenes (Table 3). The results are highly encouraging given that they were obtained at room temperature and without optimization of solvent or reaction pH. Importantly, catalyst **4a** does not appear to undergo Baeyer–Villiger decomposition under the reaction conditions. Very high e.e.<sub>max</sub> was observed for epoxidation of phenylstilbene (98%, entry 6). *Trans*- or trisubstituted aromatic olefins generally afforded products with good e.e.<sub>max</sub> (entries 3–6). Since there are few examples of the asymmetric epoxidation of electron-poor alkenes with chiral dioxiranes, we tested methyl (*E*)-cinnamate. Although good e.e.<sub>max</sub> was observed, the conversion was very low (entry 7). 2-Cyclohexenone proved more reactive but the enantioselectivity was very poor (entry 8).

In summary, we have further investigated the use of esters of  $\alpha$ -hydroxy-bicyclo[3.2.1]octan-3-one as catalysts in the Oxone<sup>®</sup> epoxidation of alkenes. The highest e.e.<sub>max</sub> was obtained using the  $\alpha$ -acetoxy-oxabicyclic **4a** and the scope of this catalyst was explored. We are continuing to examine further derivatives of this ring system as well as addressing the efficient preparation of **4a** in enantiomerically pure form.

#### Acknowledgements

We thank the EPSRC and AstraZeneca (CASE award to J.R.R.) and the EPSRC (GR/M84534) for funding.

We gratefully acknowledge generous unrestricted support from Pfizer, Merck and Bristol-Myers Squibb.

#### References

1. Review: Frohn, M.; Shi, Y. *Synthesis* **2000**, 1979–2000.
2. (a) Armstrong, A.; Hayter, B. R. *Tetrahedron* **1999**, *55*, 11119–11126; (b) Tian, H.; She, X.; Shi, Y. *Org. Lett.* **2001**, *3*, 715–718.
3. (a) Armstrong, A.; Hayter, B. R. *Chem. Commun.* **1998**, 621–622; (b) Armstrong, A.; Hayter, B. R.; Moss, W. O.; Reeves, J. R.; Wailes, J. S. *Tetrahedron: Asymmetry* **2000**, *11*, 2057–2061.
4. Yang, D.; Wong, M.-K.; Yip, Y.-C. *J. Org. Chem.* **1995**, *60*, 3887–3889.
5. Esters were prepared under standard conditions (RCOCl, pyridine). All gave satisfactory spectroscopic data.
6. Bunn, B. J.; Cox, P. J.; Simpkins, N. S. *Tetrahedron* **1993**, *49*, 207–218.
7. Tian, H.; She, X.; Xu, J.; Shi, Y. *Org. Lett.* **2001**, *3*, 1929–1931.
8. (a) Hayter, B. R. Ph.D. Thesis, University of Nottingham, 1998; (b) a graph of catalyst e.e. against product e.e. (9 data points) was linear with  $R^2=0.9991$ . Reeves, J. R. Unpublished results.
9. Tu, Y.; Wang, Z.-X.; Shi, Y. *J. Am. Chem. Soc.* **1996**, *118*, 9806–9807.
10. Sato, T.; Watanabe, M.; Honda, N.; Fujisawa, T. *Chem. Lett.* **1984**, 1175–1176.